• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    United Therapeutics Corporation - Common Stock (NQ:UTHR)

    549.91 +0.75 (+0.14%)
    Delayed Quote Updated: 3:55 PM EDT, Oct 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about United Therapeutics Corporation - Common Stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
    From United Therapeutics
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Acquires Thymmune Therapeutics
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Reports First Quarter 2026 Financial Results
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
    From MannKind
    Via GlobeNewswire
    News headline image
    United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
    From United Therapeutics Corporation
    Via Business Wire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.